EverSource Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

EverSource Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.1K	Buy	447 +192	+75%	+$4.57K	﹤0.01%	2861
2025 Q4	$5.95K	Buy	255 +14	+6%	+$312	﹤0.01%	3051
2025 Q3	$4.75K	Sell	241 -808	-77%	-$16.6K	﹤0.01%	3174
2025 Q2	$22.8K	Buy	1,049 +788	+302%	+$18.6K	﹤0.01%	2197
2025 Q1	$6.33K	Buy	261 +162	+164%	+$3.65K	﹤0.01%	2382
2024 Q4	$2.07K	Buy	+99	New	+$2.13K	﹤0.01%	2700
2023 Q2	–	Sell	-18	Closed	-$298	–	2512
2023 Q1	$298	Buy	+18	New	+$297	﹤0.01%	2290

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EverSource Wealth Advisors's CPRX Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 75% in Q1 2026, buying an estimated $4.57K and bringing the position to 447 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2861.

EverSource Wealth Advisors first reported a position in CPRX in Q1 2023 and has held it in 7 quarters since. The position peaked at $22.8K in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

EverSource Wealth Advisors held 447 shares of Catalyst Pharmaceutical worth $11.1K as of Q1 2026.
EverSource Wealth Advisors bought 192 Catalyst Pharmaceutical shares in Q1 2026, an estimated $4.57K.
Catalyst Pharmaceutical made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #2861 holding.
EverSource Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 7 quarters since.
EverSource Wealth Advisors's Catalyst Pharmaceutical position peaked at $22.8K in Q2 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.